GLIOMATCH successfully completes Reporting Period 1
GLIOMATCH has successfully completed its first reporting period (RP1), marking a key milestone in advancing data-driven precision medicine for malignant glioma. A new Results page is now available, providing access to public deliverables and scientific publications.
Discover the Understanding (tumour-host interactions) Cluster projects through our video and brochure
Discover the Understanding (tumour-host interactions) Cluster and its joint work under the EU Cancer Mission through our new brochure and introductory video.
Understanding (tumour-host interactions) Cluster publishes first joint press release!
A new joint press release presents the key outcomes of the first annual meeting of the Understanding (tumour-host interactions) Cluster, held in Barcelona in January 2025. It outlines how cluster partners are strengthening collaboration, advancing data sharing strategies and contributing to policy recommendations to support cancer research and patient outcomes across Europe.
First annual meeting of the Understanding (tumour-host interactions) Cluster held in Barcelona
On 31 January 2025, partners from across the Understanding (tumour-host Interactions) Cluster (U-THI-Clust) gathered in Barcelona, Spain, for the first annual cluster meeting, organised by the THRIVE project at the Centre Esther Koplowitz (IDIBAPS). The meeting brought together representatives from the six cluster projects, namely ARTURO, GLIOMATCH, HIT-GLIO, MULTIR, SPACETIME and THRIVE, alongside the Project Officer from HaDEA.
GLIOMATCH 3rd consortium meeting takes place in Düsseldorf, Germany
From 25 to 27 March 2025, the GLIOMATCH consortium convened in Düsseldorf, Germany, for its third consortium meeting. The meeting was held in-person and hosted by the partner University of Düsseldorf (UDUS). Over 40 experts from across Europe gathered to assess progress of the past year and plan the next phase of the GLIOMATCH project.
International Day of Women and Girls in Science 2025
On the 10th anniversary of the International Day of Women and Girls in Science, GLIOMATCH celebrates the women driving our research and our commitment to gender balance in science and leadership.
World Cancer Day 2025
On World Cancer Day 2025, the GLIOMATCH project participated in the EU project showcase hosted by HaDEA, highlighting the role of EU-funded research in advancing cancer care. We have seized this opportunity to map the EU Cancer Mission project landscape.
GLIOMATCH Receives Ethical Approval for Retrospective Clinical Trials
The GLIOMATCH project has received ethical approval from the UZ/KU Leuven Ethics Committee to conduct retrospective clinical trials for adult and paediatric glioma patients. This follows earlier approvals for other project partners, setting data collection to begin in 2025,.
Spatial proteomics named 2024 Method of the Year by Nature Methods
Spatial proteomics, a technique which maps protein distributions within tissues with high resolution, is central to the GLIOMATCH project.
European Cancer Summit 2024
GLIOMATCH was featured at the European Cancer Summit 2024, held on 20–21 November in Brussels and online. We’re proud to support Europe’s fight against cancer.